A Phase I Study of HRS-5765 in Healthy Participants
Summary
ClinicalTrials.gov registry entry for Phase 1 study NCT07551167 evaluating HRS-5765 Tablet in healthy participants. The study assesses safety, tolerability, pharmacokinetics, and pharmacodynamics. Conditions studied include Heart Failure. Interventions include HRS-5765 Tablet and HRS-5765 Tablet Placebo. This is a Phase I registration record, not a regulatory approval or efficacy finding.
“The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
ClinicalTrials.gov registry entry recording a Phase 1 clinical study for the investigational drug HRS-5765 in healthy participants. The study is categorized as Phase 1 (earliest stage of human testing) and will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics. The condition under investigation is Heart Failure.
For compliance and clinical operations purposes, this registry entry represents formal documentation of an early-stage drug development program. Pharmaceutical companies, clinical investigators, and institutional review boards monitoring the drug development pipeline may track this entry for updates on Phase 1 completion and subsequent trial phases involving Heart Failure patients.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase I Study of HRS-5765 in Healthy Participants
Phase 1 NCT07551167 Kind: PHASE1 Apr 24, 2026
Abstract
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.
Conditions: Heart Failure
Interventions: HRS-5765 Tablet, HRS-5765 Tablet Placebo
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.